Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors

Pain

Volumn 75, Issue 1, 1998, Pages 111-119

  Richardson, Jennelle Durnett ^a   Kilo, Sonja ^a   Hargreaves, Kenneth M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cannabinoid; Capsaicin; Carrageenan; Hyperalgesia; Neurotransmitter release; Peripheral

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CARRAGEENAN; RIMONABANT;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; EDEMA; HYPERALGESIA; INFLAMMATION; NEUROSECRETION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; CALCITONIN GENE-RELATED PEPTIDE; CAPILLARY PERMEABILITY; CAPSAICIN; CARRAGEENAN; EDEMA; HINDLIMB; HYPERALGESIA; MALE; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SKIN;

EID: 0031779305     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00213-3     Document Type: Article

References (53)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
2. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition of G protein coupling. FEBS Lett. 375:1995;143-147.
3. Brain, S., Sensory neuropeptides in skin. In: P. Geppetti and P. Holzer (Eds.), Neurogenic Inflammation, CRC Press, Boca Raton, FL, 1996, p. 229.
4. 2+ current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
5. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
6. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M., Beglin N.C., Chippari S.M., Grego J.D., Kullnig R.K., Daley G.T. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 35:1992;124-135.
7. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels. 1:1993;121-134.
8. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
9. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
10. 2 receptors. Mol. Pharm. 48:1995;443-450.
11. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
12. Hall, W., Solowij, N. and Lemon, J., The therapeutic effects of cannabinoids. In: The Health and Psychological Consequences of Cannabis Use, National Drug Strategy Monograph Series No. 25, Australian Government Publishing Service, 1994, pp. 185-202.
13. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
14. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88.
15. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186:1995;91-94.
16. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
17. Hohmann A.G., Herkenham M. Localization of cannabinoid receptor (CB1) mRNA in neuronal subpopulations of rat spinal cord and dorsal root ganglia. Abstr. Soc. Neurosci. 23:1997;1954.
18. Hohmann A.G., Martin W.J., Tsou K., Walker M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2118.
19. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol. Rev. 43:1991;143-201.
20. Howlett A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35:1984;1803-1810.
21. Jansen E.M., Haycock D.A., Ward S.J., Seybold V.S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575:1992;93-102.
22. Johnson M.R., Melvin L.S., Althuis T.H., Bindra J.S., Harbert C.A., Milne G.M., Weissman A. Selective and potent analgetics derived from cannabinoids. J. Clin. Pharmacol. 21:1981;2715-2825.
23. Joris J., Costello A., Dubner R., Hargreaves K.M. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain. 43:1990;95-103.
24. Kilo, S., Harding-Rose, C., Hargreaves, K.M. and Flores, C.M., Peripheral CGRP as a marker for neurogenic inflammation: development of a model system for the study of neuropeptide secretion in rat paw skin, Pain, 73 (1997) 201-207.
25. 9-tetrahydrocannabinol in the rat. Eur. J. Pharmacol. 24:1973;1-7.
26. Lee M., Yang K.H., Kaminski N.E. Effects of putative cannabinoid receptor ligands, anandamide, and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 275:1995;529-536.
27. Lemberger L., Rowe H. Clinical pharmacology of nabilone, a cannabinoid derivative. Clin. Pharmacol. Ther. 18:1975;720-726.
28. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
29. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
30. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and non-saturable high density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1994;1612-1622.
31. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
32. Martin W.J., Lai N.K., Patrick S.L., Tsou K., Walker J.M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629:1993;300-304.
33. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., Walker J.M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 56:1995;2103-2109.
34. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
35. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
36. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:1996;227-236.
37. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N., Schatz A., Gopher A., Almog S., Martin B., Compton D., Pertwee R., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
38. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
39. Nagahisa A., Kanai Y., Suga O., Taniguchi K., Tsuchiya M., Lowe J., Hess H.-J. Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist. Eur. J. Pharmacol. 217:1992;191-195.
40. Rang, H.P., Bevan, S. and Dray, A., Inflammatory pain. In: P.D. Wall and R. Melzack (Eds.), Textbook of Pain, 3rd Edn., Churchill Livingstone, New York, 1994, pp. 57-78.
41. Reeh P.W. Sensory receptors in mammalian skin in an in vitro preparation. Neurosci. Lett. 66:1986;141-146.
42. 9-tetrahydrocannabinol-induced analgesia in mice. Eur. J. Pharmacol. 301:1996;75-81.
43. Richardson, J.D., Aanonsen, L., Hargreaves, K.M., Antihyperalgesic effects of spinal cannabinoids, Eur. J. Pharmacol. (1998a) in press.
44. Richardson, J.D., Aanonsen, L. and Hargreaves, K.M., Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia, J. Neurosci. 18 (1998b) 451-457.
45. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maryani J., Neliat G., Caput D., Ferrara P., Soubrié P., Parelière J.C., Le Fur G. SR 141716A, a potent and selective antagonist at the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
46. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Brelière J.-C., Le Fur G. Biochemical and pharmacological characterization of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
47. 3H]SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 58:1996;1239-1247.
48. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
49. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
50. 9-tetrahydrocannabinol (THC). J. Pharmacol. Exp. Ther. 186:1973;646-655.
51. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
52. Vinegar R., Truax J.F., Selph J.L. Quantitative studies of the pathway to acute carrageenan inflammation. Fed. Proc. 35:1976;2447-2456.
53. Yaksh T.L. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;3345-3405.